Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

(2010) Walter M. Stadler et al.   CANCER

The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms

(2010) D. Llobet et al.   EUROPEAN JOURNAL OF CANCER

Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells

(2010) S. Huang et al.   MOLECULAR CANCER THERAPEUTICS

Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention

(2009) Philip Lazarus et al.   Annals of the New York Academy of Sciences

Functional Significance of Cytochrome P450 1B1 in Endometrial Carcinogenesis

(2009) S. Saini et al.   CANCER RESEARCH

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

(2009) M. H. Kang et al.   CLINICAL CANCER RESEARCH

Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors

(2009) Philip Lazarus et al.   DRUG METABOLISM REVIEWS

Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer

(2009) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular targeted therapy for hepatocellular carcinoma

(2009) Melanie Thomas   JOURNAL OF GASTROENTEROLOGY

Acquired Activation of the Akt/Cyclooxygenase-2/Mcl-1 Pathway Renders Lung Cancer Cells Resistant to Apoptosis

(2009) W. Chen et al.   MOLECULAR PHARMACOLOGY

Estrogen Receptor  , Fos-Related Antigen-2, and c-Jun Coordinately Regulate Human UDP Glucuronosyltransferase 2B15 and 2B17 Expression in Response to 17 -Estradiol in MCF-7 Cells

(2009) D. G. Hu et al.   MOLECULAR PHARMACOLOGY

Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk

(2009) Monica McGrath et al.   Pharmacogenetics and Genomics

Mcl-1: A Gateway to TRAIL Sensitization

(2008) S.-H. Kim et al.   CANCER RESEARCH

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

(2008) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

Mcl-1 is a potential therapeutic target in multiple types of cancer

(2008) C. Akgul   CELLULAR AND MOLECULAR LIFE SCIENCES

Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines

(2008) A. Nakamura et al.   DRUG METABOLISM AND DISPOSITION

UDP-Glucuronosyltransferases (UGTs) 2B7 and UGT2B17 Display Converse Specificity in Testosterone and Epitestosterone Glucuronidation, whereas UGT2A1 Conjugates Both Androgens Similarly

(2008) T. Sten et al.   DRUG METABOLISM AND DISPOSITION

Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy

(2008) Asfar S. Azmi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5

(2008) Y. Zhang et al.   MOLECULAR CANCER RESEARCH